
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
The American Journal of Managed Care
over 29 years ago
Consideration in Pharmaceutical Conversion: Focus on Antihistaminesover 29 years ago
Issues in the Measurement of Satisfaction with Treatmentover 29 years ago
HMOs and the Efficiency of Healthcare Deliveryover 29 years ago
Abdominal Aortic Aneurysmover 29 years ago
Reducing Malpractice Risk Through More Effective Communication





